Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995482 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
A Phase 1 study of Healthy Postmenopausal Women, sponsored by Kashiv BioSciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT06995482 is a Phase 1 study of Healthy Postmenopausal Women that is actively recruiting participants, run by Kashiv BioSciences. The registered enrollment target is 40 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06995482, a Phase 1 study of Healthy Postmenopausal Women, is actively recruiting participants, sponsored by Kashiv BioSciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to evaluate if KSHN001034 demonstrates safety, tolerability, and a comparable pharmacokinetic (PK) profile to the reference product, Faslodex® (fulvestrant), which is used for the treatment of hormone receptor-positive breast cancer. Participants will: Receive either the test product (KSHN001034) or the reference product (Faslodex®) administered intramuscularly (IM) or subcutaneously (SC) at doses of low, medium, or high , with doses conducted in 5 cohorts and these participants will be healthy postmenopausal female volunteers. Dosing will be administered in a sequential cohort-wise manner across five cohorts, with DSMB oversight for safety monitoring and dose escalation. Primary Endpoint: Safety and tolerability will be assessed based on the occurrence, severity, and relationship of adverse events (AEs), including serious adverse events (SAEs). Secondary Endpoint: Pharmacokinetic (PK) parameters will be evaluated, including Cmax (maximum concentration), Tmax (time to maximum concentration), AUC (area under the curve), and T1/2 (half-life).
Conditions Studied
Interventions
- DRUG KSHN001034
Study Locations (2)
Florida
- Floridian Clinical Research LLC - Miami Lakes
Maharashtra
- Synergen Bio Pvt. Ltd. - Pune
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06995482
The ClinicalTrials.gov registry entry for NCT06995482 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kashiv BioSciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Postmenopausal Women appearing as the primary indexed condition, and to 1 intervention - of which KSHN001034 is the first listed.
NCT06995482 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Maharashtra.
Frequently Asked Questions
What is clinical trial NCT06995482 about?
NCT06995482 is a clinical study titled "Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers". The goal of this clinical trial is to evaluate if KSHN001034 demonstrates safety, tolerability, and a comparable pharmacokinetic (PK) profile to the reference product, Faslodex® (fulvestrant), which is used for the treatment of hormone receptor-positive breast cancer. Participants will: Receive ei...
What is the current status of trial NCT06995482?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-08-18. Estimated completion is 2026-06.
What conditions does trial NCT06995482 study?
This clinical trial studies the following conditions: Healthy Postmenopausal Women.
What interventions are being tested in trial NCT06995482?
The interventions under investigation include: KSHN001034 (DRUG).
Who is sponsoring clinical trial NCT06995482?
This trial is sponsored by Kashiv BioSciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995482 being conducted?
This trial has 2 study locations across Florida, Maharashtra. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Postmenopausal Women
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females
COMPLETED · Phase 1
-
Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.